Drug Use Evaluation ofVancomycin Based on Hospital Policy and Published Guidelines

Autor: Henry Krum, Lisa L Ioannides-Demos, Denis Spelman, Olga Vujovic, Craig R Rayner, W. John Spicer, Nicholas Tong
Rok vydání: 1998
Předmět:
Zdroj: The Australian Journal of Hospital Pharmacy. 28:394-399
ISSN: 0310-6810
DOI: 10.1002/jppr1998286394
Popis: Aim: To evaluate the appropriateness of vancomycin inpatient use at a tertiary referral teaching hospital against existing hospital guidelines and other published guidelines on vancomycin usage (the US Hospital In­ fection Control Practices Advisory Committee [RICPAC]) guidelines, and the Victorian Drug Usage Advisory Comminee [VDUAC] guidelines). Methods: Patients who commenced vancomycin dur­ ing a 2-week period in hospital wards and operating theatres were identified. Information collected included antibiotic allergy, admission diagnosis, indication and duration of vancomycin use, microbiological results, dosage and adverse events. The appropriateness of vancomycin use was assessed using the various guide­ lines after consultation with an independent infectious diseases physician. Results: Fony-four courses (41 patients) were initi­ ated during the study period. Eight courses (18%) in­ volved treatment of a documented penicillin allergy. Courses were spread across prophylaxis (16), empiric (19) and guided therapy (9). Inappropriate courses according to the guidelines were Alfred hospital guide­ lines (0), RICPAC guidelines (8) and the VDUAC guide­ lines (II). Conclusion: The results highlighted differing consen­ sus opinions (indicated by differences between the three sets of guidelines) that have evolved over the last few years on the appropriate use of vancomycin. As a con­ sequence, the hospital guidelines on vancomycin have been updated. The DUE was also presented to medical staff at a professorial meeting with the outcome that a mandatory antibiotic review period was reinforced and was amended to include registrar/consultant review only. The effectiveness of such interventions will be re­ examined as part of the DUE process. Aust] Rasp Pharm 1998; 28: 394-9.
Databáze: OpenAIRE
Externí odkaz: